Micrometastasis-derived models enable drug testing for early-stage, high-risk melanoma patients
Kathrin Weidele(Fraunhofer Institute for Toxicology and Experimental Medicine), Christoph A. Klein(Fraunhofer Institute for Toxicology and Experimental Medicine)
Cited by 1
Related Papers
Genetic alterations driving metastatic colony formation are acquired outside of the primary tumour in melanoma
|Nature Communications|2018|89
Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during periods of clinical latency
|bioRxiv (Cold Spring Harbor Laboratory)|2020|0